XERS: XP-8121 and RECORLEV drive strong growth, targeting major unmet needs and expanding market share
Revenue growth is accelerating, driven by strong performance of three main products and high gross margins. XP-8121 targets a large unmet need in hypothyroidism, with a robust development and commercialization plan. RECORLEV continues to outperform, and further investments in infrastructure and pot…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.